Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical , Trasplante de Células Madre Hematopoyéticas , Leucemia Mieloide Aguda , Leucemia-Linfoma Linfoblástico de Células Precursoras , Trasplante de Células Madre de Sangre del Cordón Umbilical/efectos adversos , Sangre Fetal , Células Madre Hematopoyéticas , Humanos , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapiaAsunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Antineoplásicos/efectos adversos , Citomegalovirus/fisiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Paraproteinemias/etiología , Acondicionamiento Pretrasplante/efectos adversos , Femenino , Humanos , MasculinoAsunto(s)
Antineoplásicos/efectos adversos , Bencenosulfonatos/efectos adversos , Trasplante de Células Madre Hematopoyéticas , Policitemia/inducido químicamente , Piridinas/efectos adversos , Donante no Emparentado , Adulto , Antineoplásicos/administración & dosificación , Bencenosulfonatos/administración & dosificación , Humanos , Leucemia Mieloide Aguda , Masculino , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Policitemia/tratamiento farmacológico , Piridinas/administración & dosificación , Sorafenib , Trasplante HomólogoRESUMEN
HLA-G molecules are HLA class Ib antigens characterized by tolerogenic and immunoinhibitory functions. The HLA-G 14-bp insertion/deletion (ins/del) polymorphism controls protein expression and seems to be implicated in both MTX treatment response and SCT outcome. The aim of our study is to evaluate the role of HLA-G 14 bp polymorphism in subjects affected by hematological malignancies undergoing allo-SCT and receiving MTX therapy for GvHD prophylaxis. We performed a retrospective analysis of HLA-G 14 bp polymorphism using a specific PCR in 47 recipients and in their respective donors, and evaluated the correlation with the incidence of aGvHD, OS and disease-free survival (DFS) after allo-SCT. We did not observe any correlation between this polymorphism and the risk of aGvHD occurrence. On the contrary, we found that the recipients with a 14 bp ins/14 bp ins genotype were characterized by a lower OS and DFS in univariate and multivariate analysis (OS=OR: 3.235; DFS=OR: 3.302). These data indicate a role for recipient HLA-G 14 bp polymorphism in allo-SCT immunotolerance status and follow-up.